StocksFin Logo
AbCellera Biologics Inc. country of incorporation
|
|
Dr. Carl L. Hansen
|
475 employees
NASDAQ | Healthcare | Biotechnology
Canopy Growth Corporation country of incorporation
|
|
Mr. David Klein
|
3,151 employees
NASDAQ | Healthcare | Drug Manufacturers—Specialty & Generic
Q322 reported Nov 8, 2022 Reporting Period
$101.38M 1740.6% vs. Q321 Revenues Q322
85.17% -14.8% vs. Q321 Gross Profit Margin
26.26% 106.8% vs. Q321 Net Profit Margin
-141.3M ! -2282% vs. Q321 Free Cash Flow Q322
$0.09 212.5% vs. Q321 EPS Q322
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q322
Q223
Q223 reported Nov 9, 2022 Reporting Period
$117.86M -10.3% vs. Q222 Revenues Q223
3.24% 106% vs. Q222 Gross Profit Margin
-188.19% ! -2135.8% vs. Q222 Net Profit Margin
-135.75M ! -57.9% vs. Q222 Free Cash Flow Q223
$-0.47 ! -1466.7% vs. Q222 EPS Q223
-
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q322
Q223
Loading...
Loading...
Loading...
Loading...
Ratios
As of
Sep 30, 2022
Sep 30, 2022
Quick Ratio
9.19
2.31
Current Ratio
9.86
2.84
Cash Ratio
3.51
1.38
Price to Book
2.26
1
Price to Sales
27.83
13.76
Price to Earnings
26.5
-1.83